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BACKGROUND: In a randomised phase III trial, sunitinib significantly improved efficacy over interferon-a (IFN-a) as first-line therapy for
metastatic renal cell carcinoma (mRCC). We report the final health-related quality of life (HRQoL) results.
METHODS: Patients (n¼750) received oral sunitinib 50mg per day in 6-week cycles (4 weeks on, 2 weeks off treatment) or
subcutaneous IFN-a 9 million units three times weekly. Health-related quality of life was assessed with nine end points: the Functional
Assessment of Cancer Therapy–General and its four subscales, FACT–Kidney Symptom Index (FKSI-15) and its Disease-Related
Symptoms subscale (FKSI-DRS), and EQ-5D questionnaire’s EQ-5D Index and visual analogue scale. Data were analysed using mixed-
effects model (MM), supplemented with pattern-mixture models (PMM), for the total sample and the US and European Union (EU)
subgroups.
RESULTS: Patients receiving sunitinib reported better scores in the primary end point, FKSI-DRS, across all patient populations
(Po0.05), and in nine, five, and six end points in the total sample, in the US and EU groups respectively (Po0.05). There were no
significant differences between the US and EU groups for all end points with the exception of the FKSI item ‘I am bothered by side
effects of treatment’ (P¼0.02). In general, MM and PMM results were similar.
CONCLUSION: Patients treated with sunitinib in this study had improved HRQoL, compared with patients treated with IFN-a.
Treatment differences within the US cohort did not differ from those within the EU cohort.
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In the United States and Europe, kidney cancer is estimated to
account for approximately 4% of all new cases of cancer (Jemal et al,
2008). The annual incidence of cancer of the kidney and renal pelvis
in the United States in 2008 is estimated to be 54390, with
approximately 13010 deaths per year (Jemal et al, 2008). In the 25
countries making up the European Union (EU), more than 63000
new cases of renal cell carcinoma (RCC) were diagnosed in 2006,
resulting in an estimated 26000 deaths annually (Ferlay et al, 2007).
The prognosis for patients with metastatic RCC (mRCC) has
been historically poor, with only 10% of patients surviving beyond
5 years (US National Institutes of Health, 2006). Patients living
with mRCC can suffer significant symptoms, even with the
resection of primary tumours and metastatic sites (Williams
et al, 2004). Health-related quality of life (HRQoL) outcomes are
an important assessment tool to measure disease- and treatment-
related symptoms directly reported by patients.
A number of health status scales are available for the
measurement of HRQoL and disease- and treatment-related
symptoms in cancer patients (de Haes et al, 1990; Cella et al,
1993; Rabin and de Charro, 2001), including two validated scales
that are specific to RCC: the Functional Assessment of Cancer
Therapy–Kidney Symptom Index (FKSI) and the RCC Symptom
Index (Cella et al, 2006; Harding et al, 2007). Factors such as age,
race, marital status, education level, income, and employment have
been shown to affect HRQoL in cancer patients (Movsas et al,
2006) and may influence outcomes assessed using these scales.
Cultural differences may also affect patients’ responses to
questionnaires (Wild et al, 2005). These variables should be
considered when interpreting data and making regional compar-
isons from international multi-centre studies.
Sunitinib malate is an oral multi-targeted receptor tyrosine
kinase inhibitor of vascular endothelial growth factor receptors 1,
2, and 3, platelet-derived growth factor receptors, stem cell
factor receptor, colony-stimulating factor 1 receptor, glial cell-
line-derived neurotrophic factor receptor (Rearranged during
Transfection), and FMS-like tyrosine kinase 3, with anti-tumour
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sand anti-angiogenic effects (Abrams et al, 2003; Mendel et al, 2003;
Murray et al, 2003; O’Farrell et al, 2003; Kim et al, 2006; Pfizer Ltd,
2009). Sunitinib has been approved multinationally for the
treatment of advanced RCC and for gastrointestinal stromal
tumours after disease progression on or intolerance to imatinib
mesylate therapy (Pfizer Ltd, 2009).
In an international randomised phase III trial, sunitinib showed
statistically significant improvement in progression-free survival
and objective response rate compared with interferon-a (IFN-a)a s
first-line therapy for mRCC (Po0.001), and longer median overall
survival compared with IFN-a (Motzer et al, 2007, 2009). An
interim analysis of the trial data also showed superior HRQoL
benefits with sunitinib compared with IFN-a (Motzer et al, 2007;
Cella et al, 2008) . Here we report updated HRQoL results based on
the final data for this trial, including an analysis of geographical
differences.
METHODS
Full details of the study design have been previously reported by
Motzer et al (2007). This study was conducted in accordance with
the Declaration of Helsinki Principles and Good Clinical Practice
Guidelines. All patients provided written informed consent.
Patients and study design
Male and female patients aged X18 years with mRCC with a
component of clear cell histology were eligible for enrollment in
this study. Other eligibility criteria have been previously reported
(Motzer et al, 2007). Patients were excluded if they had a severe,
acute, or chronic medical or psychiatric condition, or a laboratory
abnormality that could increase the risk associated with study
participation or study drug administration, or that could interfere
with the interpretation of study results, or in the judgment of the
investigator makes the patient inappropriate for entry.
In this phase III trial, patients were randomised to receive either
sunitinib or IFN-a in repeated 6-week cycles: oral sunitinib was
initiated at a starting dose of 50mg per day on a schedule of
4 weeks on treatment followed by 2 weeks off treatment (Schedule
4/2) and IFN-a was administered as a subcutaneous injection on 3
non-consecutive days per week at a dose of three million units
(MU) in the first week, six million units in the second week, and
nine million units thereafter. Dose modifications were allowed for
toxicity management in both treatments.
Health-related quality of life assessments
Health-related quality of life was assessed using three validated
self-reported questionnaires: the FKSI-15 (Cella et al, 2006), the
Functional Assessment of Cancer Therapy–General (FACT-G)
(Cella et al, 1993), and EuroQoL Group’s EQ-5D self-report
questionnaire (Rabin and de Charro, 2001). Full details of these
questionnaires and their application in this study were reported by
Cella et al (2008).
The questionnaires were completed on days 1 and 28 of each
42-day treatment cycle, and at the end of treatment or on study
withdrawal. Non-English speakers were provided with question-
naires in their preferred language.
Nine HRQoL end points were derived from the three
questionnaires, including: (1) the FKSI-15 total score, (2) FKSI-
15’s FKSI-Disease-Related Symptoms (FKSI-DRS) subscale (Cella
et al, 2007), and (3) the FACT-G total score, (4–7) FACT-G’s four
subscales: physical, social/family, emotional, and functional well-
being (PWB, SFWB, EWB, and FWB respectively), and (8–9) EQ-
5D questionnaire’s EQ-5D Index (EuroQol, 1990; Rabin and de
Charro, 2001) and visual analogue scale (EQ-VAS) (de Boer et al,
2004). The FKSI-DRS subscale score was prospectively specified as
the primary HRQoL end point.
All HRQoL end points were reported for the total sample (US,
EU, Australia, Brazil, Canada, and Russia). In addition, these end
points were examined to determine any differences between
treatment arms and between the US and European (EU; France,
Germany, Italy, Poland, Spain, United Kingdom) groups.
Statistical analyses
All analyses were conducted on the intention-to-treat population.
Patient demographics and characteristics were described using
frequency distributions, means, and standard deviations. Comple-
tion of the questionnaires was defined as responses to more than
80% of items in the overall FACT-G and more than 50% of items in
the FKSI-15, FKSI-DRS, and FACT-G subscales. All patients with a
baseline assessment and at least one post-baseline measurement
were included in the analysis. Patients (n¼25) who crossed over
from IFN-a to sunitinib treatment were included in the analyses
with the original randomisation assignment. Patients with no post-
baseline assessment were excluded.
Estimated (or predicted) means were calculated for each end
point and for each treatment, as estimated using the repeated-
measures mixed-effects model (MM), controlling for time,
treatment, country, treatment-by-time, and treatment-by-country
interactions, and baseline (cycle 1, day 1) score (Fairclough, 2002;
Singer and Willett, 2003; Fitzmaurice et al, 2004). Means within
treatment group and differences in means between treatment
groups were estimated across the entire span of the post-baseline
period and all available observations.
With the exception of the individual items of FKSI-15,
sensitivity analyses to MM on HRQoL total and subscale scores
were performed using pattern-mixture models (PMM) (Little,
1994; Hedeker and Gibbons, 1997), which helps interpret results
when data are not missing at random. Results are not overly
dependant on the nature of missing data if results from MM and
PMM are similar. The main difference from MM is the addition of
the new variable ‘Pattern’ and interaction terms of ‘Pattern’
variable with all other predictors (except ‘Baseline’). Patterns were
defined according to the dynamics of the attrition process.
In applying the pattern-mixture methodology, we needed to
choose the number of patterns and how they are distributed over
the study population. We graphed the percentage of patients with
data up to a certain cycle. From this depiction three distinct
patterns emerged: an exponential decrease in the number of
patients from cycle 1 to cycle 10, then a modest linear decrease in
the number of patients from cycle 11 to cycle 21; followed by a
more pronounced linear decrease in the number of patients after
cycle 21. On the basis of these observations, we selected three
patterns with each cycle belonging to one of the patterns.
Data were analysed using SAS 8.2 (SAS Institute, Cary, NC,
USA). Statistical significance for between-treatment differences
was set at Po0.05. No adjustments were made for multiple
comparisons in this supplemental analysis.
Estimated means for US and EU groups were calculated for each
end point and each treatment arm based on the model described
above. Estimations for the EU group were performed over the
balanced population, that is, as if every country comprising the EU
group had the same number of patients in the study.
RESULTS
Patient baseline characteristics
A total of 750 patients were randomly assigned to receive sunitinib
(n¼375) or IFN-a (n¼375). The US group consisted of 347
patients. The EU group (274 patients) comprised patients enrolled
QoL in sunitinib-treated patients with mRCC
D Cella et al
659
British Journal of Cancer (2010)102(4), 658–664 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sin France (n¼82), Germany (n¼17), Italy (n¼24), Poland
(n¼103), Spain (n¼27), and the UK (n ¼21). Patients were
evenly distributed between the two treatments arms within each
geographical group and there were no significant differences
between treatment groups (Table 1). Patients had received up to 30
cycles of treatment at the time of the final analysis.
Questionnaire completion rates
A total of 692 patients (92%) had at least one post-baseline
observation for each of the FACT-G, FKSI-15, and EQ-5D
questionnaires. In the US group, an equal number of patients,
320 (92%) each, completed the FACT-G and FKSI-15 question-
naires for at least one treatment cycle; 319 patients (92%)
completed the EQ-5D questionnaire. In the EU group 252 (92%),
252 (92%), and 253 (92%) patients completed the FACT-G, FKSI-
15, and EQ-5D questionnaires respectively.
In both study populations, completion rates were slightly lower
in the IFN-a treatment arm compared with the sunitinib treatment
arm. The completion rates in the US sample were 96.6% (173 of
179) for sunitinib and 87.5% (147 of 168) for IFN-a; the completion
rates in the EU sample were 96.3% (130 of 135) for sunitinib and
87.8% (122 of 139) for IFN-a.
Questionnaire assessments
Primary HRQoL end point: FKSI-DRS For the primary end point,
FKSI-DRS, differences in estimated means significantly favoured
sunitinib over IFN-a in the total sample and in both the US and EU
groups (all P’so0.05; Table 2).
Patients receiving sunitinib reported higher FKSI-DRS scores
than those receiving IFN-a, with a significant difference in the
overall means (2.36, Po0.0001; MM; Table 2). In examining the
nine items in the FKSI-DRS (Table 3, bold items), the differences
in means significantly favoured sunitinib (Po0.05) in six of nine
items (lack of energy, fatigue, coughing, breathlessness, weight
loss, and fever).
Secondary HRQoL end points
As with the primary end point (FKSI-DRS), differences in
estimated means for FKSI-15 (total score), FACT-G (total score
and all domains), EQ-5D Index, and EQ-VAS were all significantly
favourable for sunitinib compared with IFN-a in the total sample
(all P’so0.05; Table 2).
In the US group, all end points, with the exception of the EQ-5D
scores, were significantly better in the sunitinib group than in the
IFN-a. In the EU group, between-treatment differences were
significant in five of nine end points favouring sunitinib over IFN-
a (Table 2). There were no significant treatment differences
between the US and EU groups for all of these total and subscale
scores for the HRQoL end points (Table 2).
FKSI-15 Higher (more favourable) FKSI-15 scores at each cycle
were observed for sunitinib treatment than for IFN-a in patients in
the total sample (Tables 2 and 3). Patients on sunitinib treatment
reported higher FKSI-15 scores than those on IFN-a treatment
with a significant difference in the overall means (4.06, Po0.0001;
MM, Table 2). The difference in means significantly favoured
sunitinib compared to IFN-a (Po0.05) for 10 of the 15 FKSI
Table 1 Baseline patient characteristics
Total sample
(n¼750)
US group
(n¼347)
a
EU group
(n¼274)
a Total US vs
total EU
Sunitinib
(n¼375)
IFN-a
(n¼375)
Sunitinib
(n¼179)
IFN-a
(n¼168)
Sunitinib
(n¼135)
IFN-a
(n¼139)
diff. US vs EU
P-value
Mean age, years (range) 61 (27–87) 60 (34–85) 61 (39–87) 60 (34–85) 61 (27–80) 60 (39–82) 0.8735
Male/female (%) 71/29 72/28 78/22 65/35 65/35 83/17 0.5172
Race/Ethnicity (%) 0.0004
(o0.0001
b)
Asian 1.87 3.20 1.68 3.57 0.74 0.72
Black 1.07 2.67 1.12 4.76 0.74 1.44
Not allowed to ask 0.27 0.27 0 0.60 0 0
Not listed 2.40 3.47 5.03 5.95 0 1.44
White 94.40 90.40 92.18 85.12 98.52 96.40
Previous nephrectomy (%) 90 89 92 91 90 91 0.7363
Previous radiation therapy (%) 14 14 13 12 16 14 0.3428
Common sites of metastases (%)
Lung 78 79 83 82 71 77 0.0152
Liver 26 24 30 27 24 19 0.0601
Bone 30 30 31 26 31 30 0.5115
Lymph nodes 58 53 53 46 67 60 0.0004
Number of disease sites (%) 0.0837
1 1 41 91 11 81 72 5
2 2 93 03 13 02 72 8
X3 5 75 15 85 15 64 7
ECOG PS (%) 0.0115
(0.0075
c)
0 6 26 16 76 85 75 8
1 3 83 83 33 14 34 0
2 010102
Abbreviations: IFN-a¼interferon-a; ECOG PS¼Eastern Cooperative Oncology Group.
aIn our previous publication (Cella et al, 2008) one patient in the US sample was
inadvertently assigned to the EU sample. This paper, with 274 (instead of 275) patients in the EU group and 347 (instead of 346) in the US group, gives the correct allocation.
bAll
but ‘white’ races collapsed in a ‘not white’ category.
cECOG 1 and 2 collapsed in one category, ECOG X1.
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sitems in the total sample (Table 3). Interferon-a was not
superior to sunitinib in any of the items in the subscales.
Between-treatment differences did not significantly differ between
US and EU groups across all end points, with the exception of FKSI
symptom ‘I am bothered by side effects of treatment’ (P¼0.0209;
Table 3).
FACT-G assessments The differences in scores between patients
receiving sunitinib and those receiving IFN-a were statistically
significant for the FACT-G total score in the total sample and in
both US and EU groups (Table 2). Patients receiving sunitinib
reported higher FACT-G scores than those receiving IFN-a, with a
significant difference in the overall means (6.62, Po0.0001; 6.08,
Po0.0001; 4.83, P¼0.0036 respectively; MM).
Similarly, for the FACT-G subscales, differences in scores
between the two treatment groups significantly favoured sunitinib
over IFN-a in the total sample and in the US groups. In the EU
group the differences in score between the two treatments were not
significant for three of the four subscales (Table 2).
EuroQoL assessments The overall post-baseline mean treatment
difference for the EQ-5D Index in the total sample was estimated to
be 0.05 points in favour of sunitinib (P¼0.0078; Table 2). The
overall mean treatment difference for EQ-VAS was estimated to be
7.70 in favour of sunitinib (Po0.0001; Table 2).
In the US and EU groups, the differences between the two
treatment groups were not significant for EQ-5D score, but were
significant for EQ-VAS score (P¼0.0076 and 0.0177 respectively).
Table 2 Model means of HRQoL end points across all available post-baseline observations (mixed-effects model)
Total group EU group US group US vs EU
Symptoms and
HRQoL end points SU IFN-a Diff. P-value SU IFN-a Diff. P-value SU IFN-a Diff. P-value
Diff. US vs
diff. EU P-value
FKSI-15 45.47 41.41 4.06 o0.0001* 44.91 41.99 2.93 0.0051* 45.40 42.36 3.04 o0.0001* 0.11 0.9203
FKSI-DRS 29.90 27.53 2.36 o0.0001* 29.53 27.99 1.54 0.0048* 29.29 27.72 1.57 o0.0001* 0.03 0.9645
FACT-G total score 80.49 73.88 6.62 o0.0001* 79.34 74.51 4.83 0.0036* 82.84 76.76 6.08 o0.0001* 1.25 0.4919
Physical well-being 21.61 19.72 1.89 0.0004* 21.30 20.43 0.87 0.2064 21.40 19.93 1.48 0.0023* 0.60 0.4353
Social well-being 22.46 21.51 0.95 0.0127* 21.78 21.08 0.71 0.1297 23.83 22.69 1.13 0.0044* 0.43 0.4099
Emotional well-being 18.17 17.18 0.98 0.0023* 17.92 17.14 0.77 0.0548 18.72 17.94 0.78 0.0175* 0.01 0.9807
Functional well-being 18.18 15.45 2.73 o0.0001* 17.77 15.88 1.89 0.0084* 19.47 17.23 2.25 o0.0001* 0.36 0.6477
EQ-5D Index 0.75 0.69 0.05 0.0078* 0.72 0.71 0.01 0.7127 0.77 0.75 0.02 0.2467 0.01 0.6862
EQ-VAS 73.95 66.25 7.70 o0.0001* 72.55 67.22 5.33 0.0177* 75.50 71.14 4.36 0.0076*  0.97 0.6980
Abbreviations: SU¼sunitinib; IFN-a¼interferon-a; Diff.¼sunitinib vs IFN-a; FKSI-15¼FACT–Kidney Symptom Index15 item; FKSI-DRS¼FKSI disease-related symptom
subscale. FACT-G¼Functional Assessment of Cancer Therapy–General; EQ-5D Index¼EuroQoL health-utility index
; EQ-VAS¼EQ visual analogue scale. *significant P-values
(P o 0.05).
Table 3 Model means of FKSI-15 item scores across all available post-baseline observations (mixed-effects model)
Total group EU group US group US vs EU
FKSI-15 items SU IFN-a Diff. P-value SU IFN-a Diff. P-value SU IFN-a Diff. P-value
Diff. US vs
diff. EU P-value
Signs and symptoms
I am losing weight 3.56 3.35 0.21 0.0037* 3.53 3.37 0.16 0.0661 3.48 3.35 0.13 0.0661  0.03 0.7998
I have had blood in my urine 3.98 3.98  0.00 0.9168 3.97 3.98  0.00 0.9628 3.97 3.98  0.01 0.4155  0.01 0.7304
I have a lack of energy 2.62 2.21 0.41 o0.0001* 2.56 2.26 0.30 0.0428* 2.46 2.14 0.32 0.0009* 0.01 0.9293
I feel fatigued 2.62 2.35 0.27 0.0078* 2.57 2.41 0.16 0.2643 2.45 2.19 0.26 0.0074* 0.10 0.5366
I have pain 3.06 2.92 0.14 0.0639 2.99 2.98 0.01 0.9235 3.07 2.98 0.08 0.3284 0.07 0.5531
I have bone pain 3.28 3.13 0.15 0.0819 3.21 3.17 0.04 0.7628 3.37 3.23 0.14 0.0879 0.10 0.5057
I am bothered by fevers 3.88 3.59 0.29 o0.0001* 3.86 3.63 0.23 o0.0001* 3.89 3.66 0.23 o0.0001*  0.00 0.9939
I am bothered by side effects
of treatment
2.71 2.66 0.05 0.6656 2.63 2.81  0.17 0.2186 2.67 2.47 0.21 0.0528 0.38 0.0209*
Respiratory symptoms
I have been coughing 3.48 3.12 0.36 o0.0001* 3.38 3.21 0.17 0.0551 3.46 3.27 0.19 0.0118* 0.02 0.8518
I have been short of breath 3.35 2.98 0.37 o0.0001* 3.33 3.07 0.26 0.0066* 3.24 3.01 0.23 0.0084*  0.02 0.8302
Quality of life
I am able to enjoy life 2.66 2.37 0.29 0.0047* 2.58 2.33 0.25 0.1096 2.96 2.64 0.31 0.0001* 0.06 0.7226
I am sleeping well 2.69 2.39 0.31 0.0030* 2.62 2.53 0.09 0.4740 2.79 2.65 0.14 0.0921 0.06 0.6902
I have a good appetite 2.33 2.04 0.29 0.0344* 2.28 1.88 0.40 0.0322* 2.58 2.36 0.23 0.0512  0.18 0.4050
I am able to work 2.30 1.90 0.40 o0.0001* 2.21 1.92 0.29 0.019* 2.57 2.35 0.22 0.0328*  0.07 0.6267
Emotional symptom
I worry that my condition will
get worse
2.68 2.55 0.13 0.0969 2.59 2.46 0.13 0.269 2.82 2.63 0.19 0.0241* 0.06 0.6405
Abbreviations: SU¼sunitinib; IFN-a¼interferon-alfa; Diff.¼sunitinib vs IFN-a; *Significant P-values (Po0.05). FKSI-15¼Functional Assessment of Cancer Therapy–Kidney
Symptom Index15 item; the nine bold items make up the Disease-Related Symptoms subscale (FKSI-DRS).
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sSensitivity analyses
In general, the PMM results were consistent with those results
from the MM (Figure 1). Similar to the MM results on the total and
subscale scores, the MM results on the total and subscale scores of
HRQoL did not show any statistical discrepancy between US
treatment differences and EU treatment differences (Figure 1).
DISCUSSION
In this phase III trial, sunitinib was associated with superior
HRQoL compared with IFN-a in patients with mRCC, Po0.01 as
measured by overall health status (EQ-5D Index and EQ-VAS),
cancer-specific HRQoL (FACT-G and its subscales), and Po0.0001
as measured by kidney cancer-related symptoms (FKSI-15 and
FKSI-DRS) (Cella et al, 2008). The results reflect between-
treatment differences rather than within-treatment improvement
compared with baseline.
Although patients were aware of the assigned treatment arm,
which could potentially bias the responses to the HRQoL
questionnaires in favour of sunitinib, this was substantially
mitigated by several factors. Assessments were conducted and
measured uniformly between treatment groups, and through
control of the baseline HRQoL covariates and use of the
random-effects model, the analysis incorporated and controlled
for the propensity to respond in a certain way.
Overall, FKSI-DRS scores, the primary HRQoL end point of this
study, showed that patients receiving sunitinib had fewer severe
disease-specific symptoms (lack of energy, fatigue, coughing,
breathlessness, weight loss, and fever) than did patients treated
with IFN-a. Patients receiving sunitinib also reported better scores
for FKSI-15, FACT-G, EQ-5D Index, and EQ-VAS, the secondary
HRQoL end points. Although it cannot be ruled out, it is unlikely
that these post-treatment differences could have been due to
unobserved pre-treatment differences in comorbid conditions (or
other factors) as the large number of patients randomised to each
treatment would be expected to make the treatment groups
equivalent in known and unknown ways. Therefore, any noticeable
post-treatment difference is most reasonably attributable to the
intervention, which was controlled by random assignment. More-
over, if baseline comorbid conditions (or other factors) were
related to the HRQoL outcome score, they would also likely be
related to their corresponding HRQoL baseline score, which was
adjusted for in the model (thereby increasing the precision of
estimated treatment effects).
No significant differences were found between the US and EU
groups for the FKSI-DRS, FACT-G, EQ-5D, and EQ-VAS, implying
no difference in treatments (sunitinib vs IFN-a) on HRQoL
outcomes in the US and EU subpopulations. FKSI-15 symptoms
also did not differ significantly between the US and EU subgroups
(with the exception of ‘I am bothered by side effects of treatment’).
For the item ‘I am bothered by side effects of treatment’, the
geographical variation observed between the US and EU subgroups
may reflect many factors, including a chance variation, a genuine
pharmacogenetic variation, cultural differences in attitudes to
illness, differences in health-care delivery or patients’ experiences,
or differences in scoring and reporting of HRQoL outcomes. But,
more likely, the geographical variation observed between the US
and EU subgroups is a trivial anomaly because the treatment
difference within each subgroup was not statistically significant
(P40.05).
Several interesting observations are worthy of comment. The
subscales of the FACT-G (physical, social, and emotional well-
being subscales) and items within the FKSI-15 were significantly
different by treatment group in the US but not in the EU
subgroups (i.e., ‘I feel fatigued’, ‘I have been coughing’, ‘I am able
to enjoy life’, ‘I worry that my condition will get worse’). In
addition, the FKSI question ‘I am bothered by side effects of
treatment’ was not significantly different in the patients in either
the IFN-a or the sunitinib arm, either when analysed in the entire
group or when analysed in the US or EU subgroups. Further, only
4 items within the 15-item FKSI significantly differentiated
treatment groups in both the US and the EU populations. These
four items were ‘I have a lack of energy,’ ‘I have been short of
breath,’ ‘I am able to work,’ and ‘I am bothered by fevers.’ The
other items on the FKSI scale did not seem to be important in
distinguishing HRQoL in the IFN-a and sunitinib treatment arms
in both the US and the EU treatment groups.
The EU group may give more variability in responses than the
US group. This would not necessarily imply any cross-cultural
issues, especially as the translated questions were validated in
European patients. More research would inform us further,
including psychometric testing of the FKSI in diverse European
samples as the instrument was developed and validated only in
English-speaking patients in the United States.
Individual items have more random variability (measurement
error) than multiple-item subscales, which tend to be more reliable
and accurate (Sloan et al, 2002). Therefore, it is not surprising that
several items on the FKSI scale did not distinguish HRQoL in the
IFN-a and sunitinib treatment arms in both the US and the EU
groups. What is important, though, is the direction of the effect:
the estimated treatment effect was in the same direction in the two
geographical groups for 14 of 15 FKSI items.
It should be noted that the primary HRQoL end point,
FKSI-DRS, showed treatment differences within the US group
and the EU group, but not between these two groups (P¼0.9645).
The other end points are considered secondary outcomes in this
study.
The main purpose of the geographical analysis was to determine
whether the treatment effect within the US group differs from the
treatment effect within the EU group. Despite there being a
significant effect (Po0.05) for some subscales and items in the US
group but not in the EU group, the treatment effect within
the US group did not really differ from that within the EU
group. Such occurrences are not uncommon. For example, an
active intervention group may show a significant change from
baseline but the control group may not. If there is no difference in
the mean changes between the two treatment groups, we would
conclude that there is no treatment effect between the two
treatment groups.
The MM used in these analyses reduced the potential for bias
caused by the varying numbers of patients in the two treatments
leaving the study over a period of time as a result of differing
efficacy. The results from the PMM, which allowed comparison
between different treatments based on the pattern of missing data,
supported and validated these findings. These results, therefore,
showed the robustness of the data from this analysis showing that
sunitinib was effective across all patient populations irrespective of
country, cultural, and treatment differences.
All patients including those who crossed over from IFN-a to
sunitinib treatment were analysed as per original randomisation
assignment. The impact of such analyses, if anything, can be
expected to make results of sunitinib benefit more conservative.
Yet, even with the inclusion of these 25 crossover patients,
sunitinib showed HRQoL benefits over IFN-a.
A recent geographical analysis of interim data from this study,
which included a European-only sample and data from only six
treatment cycles, reported similar results and conclusions overall
(Castellano et al, 2009). Some variations in results between these
two analyses probably stem from their use of different models,
different sets of data, and different objectives and hypotheses.
The results from our final analyses of HRQoL outcomes are
consistent with the previously reported interim results from the
overall sample (Cella et al, 2008) which reported superior HRQoL
outcomes for sunitinib over IFN-a. In addition, the similarity in
findings for patients in the geographical subsamples suggests that
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Figure 1 (A–C) Comparison of results between MM and PMM analyses across all available post-baseline observations. MM, mixed-effects model
difference between sunitinib and IFN-a; PMM, pattern-mixture model difference between sunitinib and IFN-a; FKSI-15, FACT–Kidney Symptom Index-15
item; FKSI-DRS, FKSI Disease-Related Symptoms subscale; FACT-G, Functional Assessment of Cancer Therapy–General; EQ-5D Index, EuroQoL health-
utility index; EQ-VAS, EQ visual analogue scale.
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sregional variations in treatment experience or underlying cultural
differences in HRQoL reporting are minimal. Although some
demographic variables were statistically significant between the EU
and US groups, in general, the differences were caused by the
relatively large sample sizes and did not have real import.
CONCLUSIONS
In this study, patients treated with sunitinib had improved HRQoL
compared with patients treated with IFN-a. In general, treatment
differences within the US cohort did not differ from treatment
differences within the EU cohort.
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